Cancer Chemotherapy and Pharmacology

, Volume 63, Issue 6, pp 1161–1163

Isolated molecular relapse in FIP1L1-PDGFRα hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose

  • Massimo Breccia
  • Daniela Cilloni
  • Laura Cannella
  • Caterina Stefanizzi
  • Agostino Tafuri
  • Angelo Fama
  • Michelina Santopietro
  • Giuseppe Saglio
  • Giuliana Alimena
Short Communication

Abstract

Imatinib is the treatment of choice for FIP1L1-PDGFRα (F/P+) positive myeloproliferative neoplasms, but little is known about optimal dose and duration of treatment to maintain complete molecular remission once achieved. We describe a case of F/P+ patients who started imatinib and reached a molecular remission, but did relapse after 15 months of therapy for poor adherence to therapy, and re-obtained remission only with standard dose of 400 mg/day. We reviewed the literature and highlights the need of quantitative molecular procedures to modulate imatinib dose.

Keywords

Imatinib Hypereosinophilic syndrome FIPL1-PDGFR-alpha Molecular remission 

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Massimo Breccia
    • 1
    • 3
  • Daniela Cilloni
    • 2
  • Laura Cannella
    • 1
  • Caterina Stefanizzi
    • 1
  • Agostino Tafuri
    • 1
  • Angelo Fama
    • 1
  • Michelina Santopietro
    • 1
  • Giuseppe Saglio
    • 2
  • Giuliana Alimena
    • 1
  1. 1.Department of Cellular Biotechnology and HematologyUniversity La SapienzaRomeItaly
  2. 2.Department of Clinical and Biological Sciences of the University of TurinSan Luigi HospitalOrbassanoItaly
  3. 3.Department of Human Biotechnology and HematologyRomeItaly

Personalised recommendations